Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event - Wikidata - awgldk - TriplyDB

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

http://www.wikidata.org/entity/Q28245213

about

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity Quantification of HER family receptors in breast cancer Novel method for rapid in-situ hybridization of HER2 using non-contact alternating-current electric-field mixing.A meta-analysis of array-CGH studies implicates antiviral immunity pathways in the development of hepatocellular carcinoma.Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification.Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.Testing for HER2 in Breast Cancer: A Continuing Evolution.Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Co Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer High-density SNP arrays improve detection of HER2 amplification and polyploidy in breast tumors HER2 in solid tumors: more than 10 years under the microscope; where are we now?HER2: biology, detection, and clinical implications The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.Genetic characterization of breast cancer and implications for clinical management Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status.Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.The human epidermal growth factor receptor 2 (HER2).Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer.Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues.HER2 assessment by silver in situ hybridization: where are we now?Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study.Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.The New Equivocal: Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.Automated Image Analysis of HER2 Fluorescence In Situ Hybridization to Refine Definitions of Genetic Heterogeneity in Breast Cancer Tissue.Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.The vanguard has arrived in the clinical laboratory: array-based karyotyping for prognostic markers in chronic lymphocytic leukemia.Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis.Problems In Determining Her2 Status In Breast Carcinoma.Investigation of molecular alterations of AKT-3 in triple-negative breast cancer.

P2860

Q27006811-A5C328B2-FB0E-4584-A152-F13776B5F22B Q27015506-F47F4A04-182B-4D8D-AA20-858017385BC7 Q27324543-7A15E968-6AA3-4C0E-9575-A26A3089AC37 Q31043530-223C9949-9634-49EC-9231-B6AEAB12ADB3 Q33643786-1365DC98-EBF8-47CB-A3F9-EF2880CE0315 Q33862786-1D40D79F-BA10-4D35-8DDD-7E6B68B60745 Q34010867-B898D6F2-5120-4C75-B55F-727BC387DFE2 Q34048024-270C9CB1-3293-4B6E-BE0D-3198750B0504 Q34248282-D27FC03D-39FC-4B4A-A6FA-6AAF077D169E Q34361300-6286120D-AC86-40F1-9BD7-7DD45CFC3C3C Q34417532-D3E307C6-0F5F-47AA-B2FF-74C20A7BFA14 Q34424285-848C8DB6-5E05-4242-892E-D51326661F51 Q34458036-0D05C007-460C-4B63-B3DC-AAB8767AAC75 Q34640536-A6706EE9-4AF9-4C6C-BBCC-8866564BD457 Q34978321-6CDED6FE-66BA-4C33-B4CC-CAA743E06F8B Q35064067-68FE57D2-72A7-4E62-9265-E1B2DEA87D2F Q35078859-4899A9FE-2634-4736-9C7A-0FFF7B3819C4 Q35211263-96633F2E-82A4-4B57-A2FA-885F82544C3B Q35622862-12D781B0-F06F-49F1-8820-1FEB29AF6DC0 Q35687706-DE37EDB2-DAD3-4BC8-91D2-C63CF24E11F8 Q35744973-B93266D9-0E5B-47E7-AB0A-804FD53D535D Q35832016-F087C111-6A4A-4786-98DF-CFD2B225343D Q35866923-D57C40BF-C162-4F85-B310-AC9EB3C7A47C Q36147178-86BD1260-065E-458E-924D-D3B6C25B109B Q37706844-514B0CD5-52F1-4604-81EB-E7906E33C692 Q37932507-A296E3DC-07BA-45D2-8C87-759A59C70D2C Q38088005-8BBE8A92-BEF8-4732-8429-B887F87CC594 Q38111772-F7962B4A-21DE-461E-BD99-283F124B85BE Q38314355-D339835D-1B0C-4663-A12B-21DB1B7A4EEA Q38394606-8DADC499-3827-4B25-81A1-A135200248F3 Q38414983-C7405907-6A6C-438E-B2C9-5893B4D7EC6F Q38549208-37313F41-E945-4D82-B882-9C33C0FD8807 Q38612634-89C1E859-5945-4D26-A99C-B70990091709 Q38656185-F70C597B-AFEC-4FE4-AF6E-FAB30950B95F Q40453735-192C20C1-AF8D-48A5-8C1B-FC86C3DAC22D Q40609808-91EA8D17-9279-4EC0-990C-45741ABB5284 Q41133771-1D011CD1-06A2-4BB3-96BD-2C18F84CAD5B Q41487356-6862BB3A-70BE-4CA5-B928-694C0F904832 Q42316292-B62B2824-0A14-4212-A012-8C8FA6C959FB Q44273702-B95F2063-B13B-41B4-A563-596DC9749491

P2860

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

http://www.wikidata.org/entity/Q28245213

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Clinical validation of an arra ...... at polysomy 17 is a rare event

@ast

Clinical validation of an arra ...... at polysomy 17 is a rare event

@en

Clinical validation of an arra ...... at polysomy 17 is a rare event

@nl

type

label

Clinical validation of an arra ...... at polysomy 17 is a rare event

@ast

Clinical validation of an arra ...... at polysomy 17 is a rare event

@en

Clinical validation of an arra ...... at polysomy 17 is a rare event

@nl

prefLabel

Clinical validation of an arra ...... at polysomy 17 is a rare event

@ast

Clinical validation of an arra ...... at polysomy 17 is a rare event

@en

Clinical validation of an arra ...... at polysomy 17 is a rare event

@nl

P1433

Q28245213-983E2F0A-31F4-4585-89B3-4035703B0373

P1476

Q28245213-8F6964FB-AA9E-4173-B2FA-7DCDCAEC3349

P2093

Q28245213-29144A94-A222-4924-A2CF-DC770D64E30B

Q28245213-2FDC1B92-65A6-4670-8189-CCE9929825C0

Q28245213-56467E2E-6EDD-448C-B342-80DBE6C93B8D

Q28245213-70A8C96D-1421-4F06-938A-699E8536A23A

Q28245213-8BF40226-EEA4-4CFE-881E-BF3CC76CEE63

Q28245213-AD5EDDE7-28E3-47AD-898C-840ADB7A3C85

Q28245213-C27CC8E2-2B46-4FC7-8B57-8BF944FC9D3C

Q28245213-CC89C0F1-F325-4321-A91F-DF70C886E034

Q28245213-E01C5856-0A3C-44C6-A040-9BD099F3AD9E

P2860

Q28245213-1348CD13-8302-4023-9B42-C38B132E62E4

Q28245213-1893B107-BCB8-4621-AE93-7469A099643C

Q28245213-1E040190-D41A-442D-8852-35C6808CE794

Q28245213-1FB8E0E2-8C42-490E-B7AB-7DC0F135633F

Q28245213-24BE722A-474F-4C93-BA25-C155263393EB

Q28245213-54E25F51-97D9-4CBC-9093-8157154BB590

Q28245213-582A08C5-DF95-4F5E-8BB2-44E70BE3419F

Q28245213-59A1DE31-E8C3-4693-A4E0-F0A9A36C6DCD

Q28245213-5A76EE3A-38D0-4793-90EC-857E09CB1B8C

Q28245213-5BB5DF66-D512-47B5-AACF-0E02BC4FE6D6

P2888

Q28245213-93E43A4D-2784-47E9-8BF8-B1F497D0083D

P304

Q28245213-713A2D96-1D76-4A06-92E7-D076B6445116

P31

Q28245213-F180B4DB-7F21-4765-8246-25D8B1FB303A

P3181

Q28245213-BF9DC80A-4FBB-43B0-8F7D-2C1E40ABA888

P356

Q28245213-9AF780D9-D5D3-486A-8938-8BE8FE479DD9

P407

Q28245213-598AA45B-862F-4A32-BAFB-6E301EAC4498

P433

Q28245213-02E00A61-7B89-4DE7-A514-D0DA381A9BA9

P478

Q28245213-3FAF6768-024F-46C4-803A-E995A0CB6049

P577

Q28245213-4350A2A4-B87D-4FE8-9673-E2D6F8CBA76C

P5875

Q28245213-62F0BE74-31D0-4613-A6CF-6946BA47FC2D

P6179

Q28245213-0D7F625A-DF6A-4514-A2C1-37C0C053A10F

P698

Q28245213-9C4C1A47-34A1-4420-AB7E-5868E9E040DD

P3181

P356

MODPATHOL.2009.78

P1433

Modern Pathology

P1476

Clinical validation of an arra ...... at polysomy 17 is a rare event

@en

P2093

Aswani R Bolla

http://www.w3.org/2001/XMLSchema#string

Chris McCaskill

http://www.w3.org/2001/XMLSchema#string

I-Tien Yeh

http://www.w3.org/2001/XMLSchema#string

Mansoor S Mohammed

http://www.w3.org/2001/XMLSchema#string

Mathew A Martin

http://www.w3.org/2001/XMLSchema#string

Mercedes E Gorre

http://www.w3.org/2001/XMLSchema#string

Rashmi K Shah

http://www.w3.org/2001/XMLSchema#string

Ryan S Robetorye

http://www.w3.org/2001/XMLSchema#string

Shelly R Gunn

http://www.w3.org/2001/XMLSchema#string

P2860

Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations

Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia

Application of array-based comparative genomic hybridization to clinical diagnostics

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.

High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization

High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays

Preservation of RNA for functional genomic studies: a multidisciplinary tumor bank protocol.

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.

Array-CGH and breast cancer.

P2888

modpathol.2009.78

P304

1169-75

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4448625

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/MODPATHOL.2009.78

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24433473

http://www.w3.org/2001/XMLSchema#string

P6179

1030485627

http://www.w3.org/2001/XMLSchema#string

P698

19448591

http://www.w3.org/2001/XMLSchema#string